JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M007097200 on September 19, 2000

J. Biol. Chem., Vol. 275, Issue 50, 39662-39670, December 15, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/50/39662    most recent
M007097200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allen, M. P.
Right arrow Articles by Wierman, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allen, M. P.
Right arrow Articles by Wierman, M. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Myocyte Enhancer Factors-2B and -2C Are Required for Adhesion Related Kinase Repression of Neuronal Gonadotropin Releasing Hormone Gene Expression*

Melissa P. AllenDagger §, Mei XuDagger §, Chan ZengDagger §, Stuart A. Tobet, and Margaret E. WiermanDagger §||**

From the Dagger  Department of Medicine and || Physiology and Biophysics, University of Colorado Health Sciences Center, Denver, Colorado 80262, the § Research Service, Veterans Affairs Medical Center, Denver, Colorado 80220, and the  Program in Neuroscience, The Shriver Center, Harvard Medical School, Waltham, Massachusetts 02452

Received for publication, August 6, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Synthesis of the hypothalamic peptide, gonadotropin releasing hormone (GnRH), is paramount for reproductive function. GnRH neurons originate in the olfactory region and migrate into the forebrain during development. We recently implicated adhesion related kinase (Ark) in GnRH neuron development based on its differential expression in two GnRH producing cell lines, GT1-7 and Gn10. The Ark membrane receptor encodes an extracellular domain resembling cell adhesion molecules and an intracellular tyrosine kinase. Ark is expressed in Gn10 cells derived from migrating GnRH neurons but not GT1-7 cells of the post-migratory phenotype. Here, we show that Ark and GnRH transcripts are colocalized in the cribriform plate at midgestation, suggesting that Ark is expressed in migrating GnRH neurons in vivo. Furthermore, we have identified the GnRH gene as a downstream target of Ark signaling. Ark inhibits GnRH gene expression in GnRH neuronal cells via the coordinated binding of myocyte enhancer factor-2B and -2C (MEF-2B and -2C) and a putative homeoprotein within the proximal rat GnRH promoter. Given that MEF-2 proteins are widely expressed in the brain, these studies provide further evidence for MEF-2 action during neuronal development. Moreover, our studies elucidate a potential role for Ark in regulating GnRH gene expression during GnRH neuronal migration.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The precisely orchestrated synthesis and pulsatile release of gonadotropin releasing hormone (GnRH)1 from neurons of the hypothalamus is essential for reproductive competence. The GnRH neurons are unique among other neurons as they are born in the olfactory placode and migrate into the forebrain during development (1, 2). Although the GnRH neuronal pathway has been well characterized during development, the factors regulating GnRH gene expression along the migratory route remain to be identified.

The scarcity (~800 neurons in the mouse) (2) and heterogeneity of the GnRH neuronal population has hindered in vivo as well as primary cell culture studies (3, 4). Thus, two immortalized GnRH neuronal cell lines have been generated by targeted tumorigenesis of the GnRH neurons (5, 6). The Gn10 GnRH neuronal line was developed by SV40 T-antigen immortalization of GnRH neurons at the time of migration and expresses low levels of GnRH (5). In contrast, the GT1-7 line was derived from an SV40 T-antigen targeted hypothalamic tumor of post-migratory GnRH neurons and synthesizes high levels of GnRH (6). The GT1-7 cells have been used extensively as a model system to identify potential regulators of GnRH gene expression and secretion in vivo (7-10).

Previously, we performed differential display on the two GnRH producing cell lines to identify novel factors regulating GnRH neuron migration and gene expression (11). Studies revealed that adhesion related kinase (Ark) was expressed in the Gn10 but not the GT1-7 cells. Axl, the human homolog of Ark, was originally isolated as a transforming gene in chronic myelogenous leukemia patients (12, 13). Subsequently, the Ark cDNA was cloned based on homology to the bek fibroblast growth factor receptor (14). Ark/Axl belongs to a novel subclass of receptor tyrosine kinases that includes Tyro3 and Mer (15). The extracellular domains of these receptors contain immuoglobulin and fibronection III repeats reminiscent of cell adhesion molecules, while the intracellular portions encode a tyrosine kinase (12). Ark/Axl and Tyro3 are highly expressed in the brain, although their physiologic roles are largely unknown (16-22).

Growth arrest specific gene 6 (Gas6) functions as the ligand for Ark, Tyro3, and Mer (23-26). The murine Gas6 is a member of the vitamin K-dependent protein family and has 44% amino acid identity with human protein S, a negative regulator of blood coagulation. Like protein S, the carboxyl terminus of Gas6 shows similarity to steroid binding globulin; however, Gas6 does not contain the thrombin cleavage site present in protein S required for negative feedback in the blood coagulation cascade (27). Although related to protein S, Gas6 does not play a role in coagulation but rather activates anti-apoptotic and mitogenic pathways in various cell types (28-32). Our studies have shown that Gn10 GnRH neuronal cells are protected from serum withdrawal induced apoptosis by Gas6-Ark signaling pathways (33). However, Gas6-Ark signaling does not stimulate Gn10 cell proliferation. These data suggest that Ark may play a role in GnRH neuronal survival during development.

In vascular smooth muscle cells, Ark stimulates chemotaxis in response to Gas6 (34, 35) and also engages in homophilic and heterophilic interactions with adjacent cells (17, 36). Similarly, preliminary studies in our laboratory suggest that Gas6-Ark signaling potentiates Gn10 neuronal migration (38). This diversity in Ark function argues that members of this receptor family may have multiple functions in vivo that may vary depending on the cell type. Indeed, mice harboring null mutations in Axl family receptors were recently generated (39). Animals lacking one or two of the receptors were generally healthy, while triple knockouts displayed multiple abnormalities. The most prominent defect was that of male sterility owing to defects in spermatogenesis. Whether other reproductive deficits exist in these animals has not been characterized.

Although several Ark signaling cascades have been defined (28-31, 33, 40), Ark-regulated genes have not been elucidated. In this report, we identified the GnRH promoter as a nuclear target of Ark signaling in GT1-7 GnRH neuronal cells. Our studies delineate a novel pathway whereby Ark negatively regulates GnRH gene expression via myocyte enhancer factors-2B and 2C (MEF-2B and -2C) in concert with a putative homeoprotein. The MEF-2 family of MADS (MCM1, agamous, deficiens, serum response factor)-box transcription factors play critical roles in the development and differentiation of skeletal, cardiac, and smooth muscle (41, 42). In vertebrates, four mef2 genes have been identified, mef2a, -b, -c, and -d (41). In addition to muscle, MEF-2 expression has been widely documented in the developing brain, but MEF-2 functions in neuronal lineages are largely unknown (43-49). Recent studies have linked MEF-2 mediated transcription to calcium-dependent neuronal survival, but the natural MEF-2 promoter targets involved await identification (50, 51). Other than GnRH, the N-methyl-D-aspartic acid receptor subunit 1 (NR1) promoter is the only other neural specific gene known to be regulated by MEF-2 (52).

In general, activation of muscle-specific genes is governed by MEF-2 proteins in combination with the MyoD family of bHLH proteins (MyoD, myogenin, Myf5, and MEF4) (42). These factors activate transcription by binding either to individual E-box (bHLH consensus) or MEF-2 sites or via adjacent E-box/MEF-2 elements (41). Non-classical regulatory mechanisms also exist wherein MEF-2 interacts with non-MyoD family members such as Sp1 (53), Oct-1 (54), thyroid hormone receptor (55), GATA factors (56), or NFAT (57) to stimulate gene expression. MEF-2 regulation of neural genes has been proposed to occur via association with neural-specific transcription factors (58, 59). Indeed, MEF-2 operates in cooperation with the neurogenic bHLH factor, MASH-1, to transactivate synthetic MEF-2 and E-box response elements (58, 59). That notwithstanding, the N-methyl-D-aspartic acid NR1 gene is synergistically activated in primary cortical neurons by MEF-2C and the ubiquitous factor, Sp1 (52).

Herein, we have identified the GnRH promoter as a downstream target of the tyrosine kinase receptor, Ark. The Ark signaling cascade converges on MEF-2B and -2C and a putative homeoprotein that in turn inhibit neuronal GnRH gene expression, thus implicating GnRH as the first physiologically relevant promoter negatively regulated by MEF-2 transcription factors. Our data suggest that Ark signaling may limit the expression of GnRH in migrating GnRH neurons via a novel pathway that culminates in the recruitment of homeoprotein and specific MEF-2 transcription factors to the GnRH promoter.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Reagents-- Purified IgG Ark 318 was raised against the Ark extracellular domain (37) and was provided by Paola Bellosta (New York University). The SCIP and Brn-4 antibodies were provided by Aimee Ryan and M. G. Rosenfled (University of California, San Diego). The anti-phosphotyrosine antibody, 4G10, was purchased from Upstate Biotechnology (Lake Placid, NY). The MEF-2A, Oct-1, and Oct-2 antibodies and the AP-1, Sp1, and Octamer consensus oligomers were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The Jun-MEF oligomer was purchased from Operon (Valencia, CA). The MEF-2D antibody was purchased from Transduction Laboratories (Lexington, KY). The MEF-2B antibody was provided by Ron Prywes (Columbia University), and the MEF-2C antibody was provided by John Schwarz (University of Texas Medical School, Houston, TX) (60).

Cell Culture-- GT1-7 (6) and Gn10 (5) cells were grown in Dulbecco's modified Eagle's medium supplemented with 5% fetal calf serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B at 37 °C in humidified 5% CO2, 95% air.

Plasmids-- The pA3LUC plasmid contains a trimerized SV40 polyadenylation signal located upstream of inserted promoter sequences resulting in minimal background luciferase activity in the promoterless vector (61). A HindIII fragment containing nucleotides -3026 to +116 of the rat GnRH promoter was ligated into the HindIII site of pA3LUC (rGnRH-LUC), placing the GnRH promoter upstream of the luciferase (LUC) coding region (62). Promoter deletion constructs were generated using convenient restriction enzyme sites and ligated into the SmaI-HindIII sites of pA3LUC (62). The hGnRH-LUC construct was generated by ligating -3832/+5 of the human GnRH promoter into pA3LUC (63). The heterologous construct (-333/-16GnRH)RSV180-LUC, contains a 180-base pair promoter fragment (-130 to +50) within the 3' long terminal repeat of the Rous sarcoma virus downstream of the rGnRH promoter fragment, -333/-16 (64). The MMTV-LUC contains sequences -1161 to +102 of the MMTV long terminal repeat (65). TRE-TK-LUC contains a trimerized 12-O-tetradecanoylphorbol-13-acetate response element upstream of pTK-LUC (66). pTK-LUC contains -109 to +18 of the HSV-TK gene and was provided by William Wood (University of Colorado Health Sciences Center). ERE-TK-LUC contains the estrogen response element from the Xenopus vitellogenin gene promoter upstream of pTK-LUC (64). PRK5-Ark contains the mouse Ark cDNA (17) (provided by Paola Bellosta, New York University). MEF-2A, MEF-2B, MEF-2C, and MEF-2D cDNAs in pcDNA1 were provided by Eric Olson (University of Texas Southwestern Medical Center). The dominant negative pcDNA1-MEF2C-S387A was provided by Jiang Han (Scripps Research Institiute) (67).

Northern Analysis-- Total RNA from GT1-7, Gn10 cells, and E13 mouse brain regions was isolated using Trizol reagent (Life Technologies, Inc., Grand Island, NY). Five micrograms of total RNA was separated by electrophoresis on a 1.4% agarose gel containing formaldehyde and transferred to nitrocellulose. Antisense RNA probes for Ark and GnRH were synthesized using digoxigenin (DIG)-labeled nucleotides (Roche Molecular Biochemicals, Indianapolis, IN). The Ark probe contained the antisense sequence spanning nucleotides 401-819 of the Ark cDNA, and the GnRH probe encoded the mouse antisense GnRH sequence. The probes were hybridized at 68 °C for 16 h in 50% formamide, 5 × SSC, 2% blocking reagent (Roche Molecular Biochemicals), 0.1% N-laurylsarcosine, and 0.2% SDS (probe concentrations, Ark, 0.4 µg/ml; GnRH, 0.1 µg/ml). The filters were washed twice in 2 × SSC, 0.1% SDS for 5 min at room temperature and twice in 0.1 × SSC, 0.1% SDS at 68 °C for 15 min. To visualize bound probe, a Roche Molecular Biochemicals DIG Nucleic Acid Detection Kit was used. Briefly, filters were washed in 0.1 M maleic acid, 0.3% Tween 20, 0.15 M NaCl, pH 7.5, and blocked for 30 min in blocking buffer (0.1 M maleic acid, 0.15 M NaCl, pH 7.5, containing 1% blocking reagent (Roche Molecular Biochemicals)). The filters were incubated in anti-DIG-alkaline phosphatase conjugate (1:5000) diluted in blocking buffer for 30 min and washed twice in 0.1 M maleic acid, 0.15 M NaCl, pH 7.5, for 15 min. Bound antibody was detected using an enzyme catalyzed color reaction with 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium salt.

Transient Transfection-- GT1-7 cells were electroporated with 10 µg of the luciferase construct (rGnRH-LUC, hGnRH-LUC, ERE-TK-LUC, alpha -subunit-LUC, MMTV-LUC, TRE-TK-LUC (-333/-16GnRH)RSV180-LUC, or RSV180-LUC), 5 µg of pRK5-Ark, and 0.5 µg of RSVbeta gal to control for transfection efficiency. The total amount of plasmid was maintained constant at 20 µg with the inclusion of empty vector, pRK5. Cells were harvested 16-18 h post-transfection, and the lysate was assayed for luciferase and beta -galactosidase activities as described previously (62). For the dominant negative MEF-2C studies, 5 µg of pcDNA1-MEF2C-S387A was used.

Western Blot Analysis-- GT1-7 and Gn10 cells were washed twice in phosphate-buffered saline at 4 °C and lysed in 0.1 ml of cell lysis buffer (150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% Triton-100, 0.1% Nonidet P-40, 1% glycerol, 1 mM dithiothreitol, 10 mM Tris-Cl, pH 7.5, supplemented with complete protease inhibitor mixture from Sigma). Following addition of lysis buffer, the cells were sonicated for 10 pulses using a Branson sonifier 250 (Branson Sonic Power Co.; settings, duty cycle 30 and output control 3). Cell debris was removed by centrifugation at 14,000 × g for 10 min at 4 °C. The protein concentration of the supernatant was determined using the BCA protein assay kit (Pierce, Inc., Rockford, IL). Twenty micrograms of protein were resolved by SDS-polyacrylamide gel electrophoresis on 7.5-12% gels and transferred to Hybond polyvinylidene difluoride (Amersham Pharmacia Biotech). For immunoprecipitation, 1.5 mg of cell lysate was immunoprecipitated with 4G10 antibody. The membranes were blocked in 5% non-fat milk/TBS-T buffer (137 mM NaCl, 0.1% Tween 20, 20 mM Tris-Cl, pH 7.6) for 1 h at room temperature or overnight at 4 °C. Membranes were incubated for 1 h in primary antibody and washed three times in TBS-T for 15 min. The membranes were incubated in horseradish peroxidase-linked secondary antibody for 30-60 min, washed three times in TBS-T for 15 min, and incubated in enhanced chemiluminescence (ECL) immunodetection reagents according to the manufacturer's instructions (Amersham Pharmacia Biotech).

Electrophoretic Mobility Shift Assay (EMSA)-- The double-stranded GnRH oligomers used in the EMSA studies are described in Table I and were synthesized as complimentary pairs (Life Technologies, Inc.). Double stranded oligomers were end-labeled using the Klenow fragment of DNA polymerase I (Life Technologies, Inc.) and [alpha -32P]dCTP (PerkinElmer Life Sciences, 3000 Ci/mmol) to a specific activity of 10,000-30,000 cpm/ng. The labeled oligomers were purified using a Sephadex G-25 spin column (5-Prime right-arrow 3-Prime, Boulder, CO). GT1-7 and Gn10 nuclear extracts were prepared as described (68). For EMSAs, nuclear extracts (5 µg) were incubated for 20 min at 4 °C in 1 mM dithiothreitol, 2.5 mM MgCl2, 10% glycerol, 0.1 mg/ml bovine serum albumin, 10-20 ng/µl poly(dG-dC), 20 mM HEPES, pH 7.9, and 50-100,000 cpm of oligomer in a total volume of 20 µl. For competition experiments, the unlabeled DNA competitors were incubated with the nuclear extracts for 20 min at 4 °C followed by another 20-min incubation in the presence of labeled oligomers. Subsequently, the reaction mixtures were resolved by electrophoresis on 5% non-denaturing polyacrylamide gels containing 3% glycerol and 0.25 × TBE (1 × TBE, 90 mM Tris borate, 1 mM EDTA). The gels were run at 4 °C for 4 h at 250 V. Following electrophoresis, the gels were dried and exposed to film at -70 °C for 16-24 h. For the combined EMSA/Western analysis, protein-DNA complexes were eluted from dried EMSA gels in Laemmli sample buffer (69) and subsequently analyzed by Western blot as described above.

Promoter Mutagenesis-- Rat GnRH promoter mutations were generated using the Quickchange Site-directed Mutagenesis System (Stratagene, La Jolla, CA) and (333/-16 GnRH)RSV180-LUC as the template. Mutant primers were synthesized by Life Technologies, Inc. The mutant primers were as follows: the Homeobox primer spanned the sequence -178/-122, the MEF-2 primer spanned the sequence -177/-97, and the E-box primer spanned the sequence -169/-94. Mutations that were generated in the GnRH promoter using these primers are indicated in Fig. 7A. The mutations were confirmed by DNA sequencing (UCHSC, Cancer Center Sequencing Core Facility).

Statistical Analysis-- Data are shown as mean ± S.E. Data were compared using the Student's t test, and p values of <0.05 were considered significant.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Ark Expression in Neuronal Cell Lines and in Vivo-- Since Gn10 and GT1-7 cells were derived during two windows of GnRH neuronal development, we performed differential display on the cell lines to identify novel factors potentially involved in the migratory process and GnRH gene expression (11). Using this method, we demonstrated that Ark is expressed in the Gn10 cells derived during GnRH neuron migration but not the GT1-7 cells of the post-migratory phenotype (Fig. 1, A and B). To establish whether Ark was expressed in GnRH neurons in vivo, Northern analysis was performed on RNA isolated from mouse brain regions at embryonic day 13 (E13), a time when the GnRH neurons are migrating and concentrated in the cribriform plate area (70, 71). Both Ark and GnRH mRNA were detected in the cribriform plate RNA but not in the basal forebrain, brainstem, or telencephalon, (Fig. 1B). Together, these data are consistent with the notion that Ark is expressed in migratory GnRH neurons during development.



View larger version (30K):
[in this window]
[in a new window]
 
Fig. 1.   Distribution of Ark and GnRH in cell lines and in vivo. A, Western analysis for Ark expression in GT1-7 and Gn10 cells (20 µg of cell lysate) using the Ark antisera, 318. B, Northern analysis for Ark and GnRH mRNA in E13 brain tissues and GnRH neuronal cell lines (5 µg of total RNA per lane). DIG-labeled antisense RNA probes for GnRH and Ark were hybridized and detected as described under "Materials and Methods."

Ark Inhibits GnRH Promoter Activity in GT1-7 Neuronal Cells-- It has previously been noted that GnRH expression levels are markedly different between the two neuronal cell lines being high in the post-migratory GT1-7 and low in the migratory Gn10 cells (Fig. 1B) (5, 6). The divergent expression of GnRH and Ark between the neuronal cell lines suggested that one of Ark's functions in GnRH neurons may be to limit GnRH gene expression during migration. To test this hypothesis, Ark was reintroduced into GT1-7 (Ark negative) cells with various promoter constructs, and transcriptional activity was assessed using a luciferase reporter. Ark repressed the full-length rat (rGnRH-LUC) and human (hGnRH-LUC) GnRH promoters to 39 and 27% of basal promoter activity, respectively (Fig. 2A). Conversely, Ark had no significant effect on other constructs tested including the vitellogenin gene estrogen response element (ERE-TK-LUC), the pituitary alpha  subunit gene promoter (alpha -subunit-LUC), or the mouse mammary tumor virus promoter (MMTV-LUC). In contrast, Ark stimulated a 12-O-tetradecanoylphorbol-13-acetate response element (TRE-TK-LUC) by nearly 4-fold. To confirm Ark expression and activation of its tyrosine kinase domain in transfected GT1-7 cells, immunoprecipitation and Western blot analysis was performed. As shown in Fig. 2B, Ark was present in cells transfected with pRK5-Ark but not vector alone (pRK5). In addition, tyrosine-phosphorylated Ark was abundant in Ark-transfected GT1-7 cells. Thus, Ark expression in immortalized GnRH neurons results in activation of its tyrosine kinase domain in the absence of ligand, Gas6. Together these data demonstrate that Ark signaling results in promoter specific activation or repression.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2.   Ark represses GnRH promoter activity in GT1-7 cells. A, GT1-7 cells were electroporated with luciferase (LUC) promoter construct (10 µg), RSV-beta -galactosidase (beta gal) (0.5 µg) and pRK5 or pRK5-Ark (5 µg). Cells were harvested after 16 h and assayed for LUC and beta -galactosidase activities. The LUC activity of cells that received empty vector, pRK5, RSV-beta gal, and the respective luciferase construct was set at 100% (Control). Data are presented as percent LUC activity of the respective control (n = 3-5 for each construct). B, upper panel, GT1-7 cells were electroporated as described and the cell lysates analyzed by Western blot with the Ark antiserum, 318. Lower panel, Ark was immunoprecipitated with the anti-phosphotyrosine antibody, 4G10, and immunoblotting was performed with the Ark 318 antibody (P-Ark, phospho-Ark).

Ark Repression Is Conferred via the Proximal GnRH Promoter-- To map the GnRH promoter regions that conferred Ark responsiveness, 5' deletion constructs were tested in GT1-7 cells. Co-expression of Ark with the full-length rat GnRH promoter (rGnRH-LUC, -3026/+116) resulted in 60% inhibition of promoter activity (Fig. 3A). Deletion to -516 and -171 maintained Ark repression, while truncation to -126 resulted in loss of Ark regulation. Thus, the Ark responsive region lies between -171/-126 of the proximal rat GnRH promoter. The Transcription Element Search System (TESS) (72) was used to identify potential cis-regulatory elements between -171/-126 of the promoter (Fig. 3B). Putative binding motifs for members of several transcription factor families were identified including the basic helix loop helix, homeodomain, zinc finger, bZIP, and MADS families.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   Ark inhibition maps to the proximal GnRH promoter. A, GT1-7 cells were electroporated with the full-length rat GnRH promoter construct (rGnRH-LUC, -3026/+116) or a 5' deletion construct (-516, -171, -126, or -73) (10 µg), RSVbeta -gal (0.5 µg), and pRK5 or pRK5-Ark (5 µg). Cells were harvested after 16 h and assayed for LUC and beta -galactosidase activities. The LUC activity of cells that received empty vector, pRK5, RSV-beta gal, and the respective luciferase construct was set at 100% (Control). Data are presented as percent LUC activity of the respective control (n = 3-4 for each construct tested; *, p < 0.05, -171 construct compared with -126 construct by the Student's t test). B, putative cis-regulatory elements between -171 and -124 of the rat GnRH promoter. The figure was generated using the Transcription Element Search Software (TESS) allowing for 20% mismatches (72). Putative binding motifs for several transcription factor families were identified (transcription factor classes are indicated in italics): the basic helix loop helix family (E12, E47, MEF-1, TFE3-S, sea urchin myogenic factor-1 (SUM-1), Myo-D), the zinc finger family (SP1, Krueppel (Kr)), the bZIP family (AP1, C/EBPbeta , and delta ), the MADS family (MEF-2), serum response factor (SRF), and the homeodomain protein family (MATalpha 1-2, Bicoid (Bcd), fushi tarazu (Ftz), HoxD8, HoxD9, HoxD10, Oct-1, Oct-4, SCIP). The SCIP (Oct-6, Tst-1) site was identified as a class III POU element in previous studies by us and others (9, 73). DNA sequences shown in boxes were mutated for the EMSA and transfection assays shown in the following figures.

MEF-2B and 2C Bind the MEF-2 Site in the Proximal GnRH Promoter-- The promoter deletion studies demonstrated that the proximal GnRH promoter between -171 and -126 conferred Ark inhibition. To identify potential nuclear targets of Ark signaling in the GnRH neuronal cell lines, EMSAs were performed with the -171/-126 promoter fragment. Initially, protein-DNA complexes from Gn10 (Ark positive) and GT1-7 (Ark negative) cells were compared (Fig. 4A). Factors from both Gn10 and GT1-7 cells bound the -171/-126 GnRH oligomer. However, the protein-DNA complexes observed from Gn10 cells (indicated by a bracket) were distinct from that of GT1-7 cells and vice versa, suggesting that factors unique to each of the neuronal cell lines bind this region of the GnRH promoter.



View larger version (35K):
[in this window]
[in a new window]
 
Fig. 4.   MEF-2 and homeoproteins bind the Ark responsive region of the GnRH promoter. A, Gn10 or GT1-7 nuclear extracts (5 µg) were subjected to EMSA with a 32P-labeled oligomer, -171/-126, (the Ark responsive region of the GnRH promoter). The bracket denotes a protein/DNA doublet specific to Gn10 (Ark positive) cells. B, an EMSA was performed with Gn10 nuclear extracts and 32P-labeled oligomer, -171/-126. The protein/DNA doublet was competed with 200 times unlabeled AP-1, Sp1, Octamer, or MEF-2 consensus element. Oligomer sequences are presented in Table I. C, an EMSA was performed with Gn10 nuclear extracts and 32P-labeled wild type or mutant (MT) oligomers spanning -157/-121 of the rat GnRH promoter. Specific mutations are described in Table I.

Although AP-1 and Sp1 consensus elements were detected within the Ark responsive promoter region (Fig. 3B), excess unlabeled AP-1 and Sp1 consensus oligomers had no effect on the Gn10 protein-DNA complexes (Fig. 4B). In contrast, formation of the Gn10 protein/DNA doublet was completely blocked upon exposure to an excess of the unlabeled MEF-2 site from the Jun promoter and substantially inhibited in the presence of the POU homeoprotein octamer consensus. These data suggested that homeoproteins and MEF-2 proteins were components of the Gn10 protein-DNA complexes.

To ascertain the promoter sequences necessary for the formation of the Gn10 complexes, mutant oligomers were tested in the gel shift (Fig. 4C, Table I). The protein/DNA doublet was detected with the wild type oligomer (-157/-121 GnRH) and Gn10 nuclear extracts. Mutation within the region containing homeoprotein consensus elements (Homeobox MT, -154 to -147) resulted in complete loss of both complexes. In contrast, only the lower complex was specifically abolished upon mutation of the MEF-2 site spanning -145 to -136 (MEF-2 MT). Mutation of the E-box motif (E-box MT, -129 to -124) within the oligomer had no effect on the protein/DNA doublet. An oligomer encoding both the Homeobox and MEF-2 mutations (Homeobox/MEF-2 MT) generated similar results to that of the Homeobox MT alone (not shown). Similarly, the combination MEF-2/E-box MT generated a protein-DNA complex identical to the MEF-2 MT alone (not shown). Taken together, these data suggested that homeodomain and MEF-2 proteins specific to Gn10 cells bind the homeobox and MEF-2 sites within the Ark-regulated promoter region.


                              
View this table:
[in this window]
[in a new window]
 
Table I
EMSA oligomers

Because the promoter deletion and gel shift studies suggested the participation of MEF-2 proteins in Ark repression, we examined MEF-2 expression in the GnRH neuronal cell lines (Fig. 5A). Four mef2 genes have been identified, mef-2a, -2b, -2c, and -2d, and antibodies specific to each MEF-2 protein have been developed (60). All four MEF-2 proteins were expressed in the two cell lines. However, MEF-2B and -2C were expressed at higher levels in the Gn10 (Ark positive) cells than the GT1-7 (Ark negative) cells.



View larger version (35K):
[in this window]
[in a new window]
 
Fig. 5.   MEF-2B and MEF-2C bind the MEF-2 element in the proximal GnRH promoter. A, Western analysis of Gn10 and GT1-7 cell lysates (20 µg/lane) for expression of MEF-2A, -2B, -2C, and -2D. The molecular weight standards to the left are in kDa. B, the protein was eluted from the lower complex of the EMSA (Fig. 4A, lane 1) and immunoblotted for MEF-2A, -2B, -2C, and -2D (69). The molecular weight standards to the left are in kDa.

To identify the MEF-2 protein(s) binding to the MEF-2 element between -145 and -136, anti-MEF-2 antibodies were tested by EMSA. Addition of anti-MEF-2B and -2C antibodies to the reactions resulted in loss of the lower band, while the anti-MEF-2A and 2D antibodies had no effect on the complexes (not shown). To confirm the binding of MEF-2B and -2C, the lower band of the protein/DNA doublet was eluted and analyzed for the presence of MEF-2 proteins by Western blot (Fig. 5B) (69). MEF-2B and -2C were detected in the protein eluted from the gel, while MEF-2A and -2D were undetectable. Together, these data confirm that MEF-2B and -2C bind the MEF-2 site in the proximal GnRH promoter.

In an effort to identify the constituents of the upper Gn10 protein-DNA complex, additional EMSAs were performed. The promoter deletion studies and EMSAs suggested that a homeodomain protein may operate in conjunction with MEF-2B and -2C to regulate the GnRH promoter. Previous studies from our laboratory demonstrated that the POU homeoprotein, SCIP (Oct-6, Tst-1), repressed GnRH promoter activity in GT1-7 cells in part through the class III POU consensus spanning -154/-147 (9, 73). However, addition of POU homeodomain protein antibodies including anti-Oct-1, Oct-2, SCIP (Oct-6, Tst-1), or Brn-4 to the reaction mixtures did not supershift or obliterate the upper band (data not shown). Thus, further studies are necessary to identify the protein(s) binding adjacent to MEF-2B and -2C in Gn10 GnRH neuronal cells.

Ark Repression Is Partially Mediated by MEF-2 Proteins-- To evaluate whether myocyte enhancer factors alone were sufficient to regulate the GnRH promoter, all four MEF-2s were tested in the transfection assay. MEF-2A, 2B, -2C, and -2D each repressed GnRH promoter activity by approximately 20% (data not shown). In addition, various combinations of the MEF-2s were tested, and promoter inhibition remained at only 20% (data not shown), suggesting that MEF-2 proteins may require additional regulatory factors to modulate the GnRH promoter.

To assess whether MEF-2 proteins were obligatory for Ark repression of GnRH gene expression, a dominant negative form of MEF-2C (MEF2C-S387A) (67) was tested (Fig. 6). MEF2C-S387A encodes a serine to alanine change at amino acid 387 within the transactivation domain. In the presence of the full-length rat GnRH promoter, Ark suppressed basal promoter activity by 55%. Dominant negative MEF-2C alone had no effect on basal promoter activity. However, in the presence of dominant negative MEF-2C, Ark inhibition of GnRH decreased to only 19%. Taken together, these data support that Ark-mediated repression of the GnRH promoter is governed in part, by MEF-2 proteins.



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 6.   Dominant negative MEF-2C partially blocks Ark inhibition of the GnRH promoter. GT1-7 cells were electroporated with the full-length rat GnRH promoter (rGnRH-LUC, -3026/+116, 10 µg), RSV-beta gal (0.5 µg), pRK5 or pRK5-Ark (5 µg), and pcDNA1 or pcDNA1-MEF2C-S387A (5 µg). Cells were harvested after 16 h and assayed for LUC and beta -galactosidase activities. The LUC activity of cells that received empty vectors, pRK5 and pcDNA1, RSV-beta gal, and rGnRH-LUC was set at 100% (open bar). Data are presented as percent LUC activity of control (n = 3-5). Values for Ark versus Ark+MEF2C-S387A were statistically different by the Student's t test, p < 0.05.

Ark Inhibition of GnRH Gene Expression Requires MEF-2 and Homeoprotein Consensus Elements-- To identify the specific promoter elements required for the Ark effect on GnRH expression, promoter mutants were generated in the context of the wild type GnRH promoter. However, mutation of the homeoprotein binding element spanning -154/-147 of the rat GnRH promoter resulted in low basal promoter activity making analysis of promoter repression technically difficult (not shown). Thus, to dissect the elements necessary for Ark inhibition of the GnRH promoter, mutants were generated within the context of a neutral heterologous promoter, RSV, lying downstream of -333/-16 of the proximal rat GnRH promoter (-333/-16 GnRH)RSV180LUC) (Fig. 7A). As shown in Fig. 7B, while the RSV180-LUC construct was not regulated by Ark, wild type (-333/-16 GnRH)RSV180LUC was inhibited by 43%. Mutations (MT) of the Homeobox, MEF-2, or E-box site individually had modest effects on Ark inhibition of GnRH (27, 26, and 32% inhibition, respectively), whereas Ark inhibition was completely abrogated in the presence of the GnRH promoter construct encoding both the Homeobox and MEF-2 motif mutations (Homeobox/MEF-2 MT). These studies confirm the functional requirement of both the MEF-2 and homeoprotein elements in Ark control of the GnRH promoter.



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 7.   The homeoprotein and MEF-2 elements are required for Ark regulation of the GnRH promoter. A, a diagram of the wild type (-333/-16 GnRH)RSV180-LUC heterologous construct used in the transfections. The mutations (MT) generated in the promoter construct are shown. B, GT1-7 cells were electroporated with empty RSV180-LUC, wild type (-333/-16 GnRH)RSV180-LUC or mutant (-333/-16 GnRH)RSV180-LUC (10 µg), RSV-beta gal (0.5 µg), and pRK5 or pRK5-Ark (5 µg). Cells were harvested after 16 h and assayed for LUC and beta -galactosidase activities. The LUC activity of cells that received empty vector, pRK5, RSV-beta gal, and the respective LUC construct was set at 100%. Data are presented as percent LUC activity of the respective control (n = 3 for each construct). The Homeobox/MEF-2 MT was statistically different from the other mutants and wild type based on the Student's t test, p < 0.05.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Prior to our studies, the nuclear effectors of Ark signaling were unknown. Herein, we have shown that Ark inhibits transcription of GnRH, the gene whose coordinated activation and inhibition is absolutely essential for normal reproductive function. The fact that Ark is expressed in migratory (Gn10 cells) rather than postmigratory (GT1-7 cells) immortalized GnRH neurons, and Ark transcripts were detected in E13 mouse cribriform plate tissue containing GnRH neurons argues that Ark is expressed in migrating GnRH neurons during development. Regarding this possibility, it should be noted that the GnRH neuronal population has not been carefully examined in the Axl family member null mice (39). Given that our studies implicate Ark function in GnRH neurons, studies are underway to determine the temporal colocalization of Ark and GnRH in the GnRH neuronal population during development.

The observation that reintroduction of Ark into post-migratory GT1-7 cells inhibited GnRH promoter activity prompted investigation of the promoter regions involved. Ark repression mapped to the sequences lying between -171 and -126 of the proximal GnRH promoter. Proteins specific to the Gn10 (Ark expressing) cells bound this region of the promoter and were competed by unlabeled octamer and MEF-2 consensus elements, but not AP-1 or Sp1 elements, thus implicating MEF-2 and homeodomain proteins in Ark regulation of the GnRH promoter. Mutagenesis of individual E-box, MEF-2, and homeoprotein consensus elements within this region had modest effects on Ark inhibition of the GnRH promoter. However, Ark regulation was completely abrogated in the presence of a GnRH promoter construct encoding both the homeoprotein and MEF-2 site mutations. Thus, the coordinated binding of both a myocyte enhancer factor(s) and a homeoprotein(s) were required for Ark inhibition. The gel shift analysis combined with the dominant negative MEF-2C studies implicated MEF-2B and -2C in Ark regulation rather than MEF-2A and -2D. Moreover, the partial effectiveness of dominant negative MEF-2C in blocking Ark repression confirmed that MEF-2 action was necessary but not sufficient in this pathway.

Although the promoter mutagenesis confirmed that a homeoprotein operated in collaboration with MEF-2B/2C to down-regulate GnRH gene expression, the identity of this factor is still under investigation. Several types of homeoprotein consensus elements were detected between -158 and -143, including binding sites for Hox, bicoid, and POU homeodomain proteins (Fig. 3B) (72). Previous studies from our laboratory showed that SCIP (Oct-6) repressed GnRH gene expression via proximal promoter elements (9, 73). Based on the EMSA data, however, the protein does not appear to be the POU homeoproteins, Oct-1 (8), Oct-2 (8), SCIP (Oct-6) (9), or Brn-42 expressed in GnRH neuronal cells. Because the mutagenesis also disrupted the Hox and bicoid motifs, our studies cannot eliminate these types of homeoproteins as potential candidates involved in Ark repression. Indeed, studies by us and others have demonstrated that the cis-acting element spanning -154 to -147 of the rat GnRH promoter is required for basal promoter activity in GT1-7 cells (63, 74). Furthermore, this site appears to integrate signals for both activation and inhibition of GnRH promoter activity, as Otx-2, a bicoid-like homeoprotein, stimulates the GnRH promoter via this region in GT1-7 cells (74). Thus, the identity of the homeoprotein(s) interacting with MEF-2B and 2C in Gn10 and GT1-7 cells may provide important insights related to both positive and negative regulation of the GnRH promoter.

Although MEF-2 isoform expression has been demonstrated both spatially and temporally in the embryonic brain (43-49), unraveling MEF-2 functions in neuronal lineages has just begun. The finding that MEF-2 regulated transcription is associated with neuronal survival implicates anti-apoptotic genes as potential MEF-2 targets (50, 51). Prior to GnRH, however, the only neural promoter having been identified as a MEF-2 target was the N-methyl-D-aspartic acid NR1 receptor promoter (52). In fetal cerebrocortical cultures, Sp1 and MEF-2C interacted to synergistically activate the NR1 gene. Given that MEF-2C and Sp1 were also expressed endogenously in these fetal cerebrocortical cultures suggests that these two factors regulate NR1 expression in vivo. Coupled with our studies of the GnRH promoter, these data provide further evidence that MEF-2 proteins may play pivotal roles in neuronal development.

The complexities of MEF-2-mediated gene regulation have been extended with recent work from Lu et al. (75). In cardiomyocytes, MEF-2 was shown to be maintained in an inactive state when associated with the class II histone deacetylases 4 and 5 (HDAC4 and -5) that deacetylate histones resulting in transcriptional repression. Under hypertrophic conditions, HDAC dissociation from MEF-2 was mediated via CaMK signaling, while subsequent MEF-2 activation occurred by mitogen-activated protein kinase phosphorylation within the MEF-2 transactivation domain. Thus, the activity of MEF-2 proteins was shown to be dependent upon phosphorylation as well as interactions with other coregulatory proteins. In T cells, MEF-2 is sequestered in an inactive state by another repressor, Cabin (76). Similar to cardiomyocytes, calcium signaling leads to MEF-2 dissociation from the inhibitory factor (Cabin). In this system, however, Cabin associates with a histone deacetylase complex consisting of mSin3A/HDAC1 and -2. Finally, the co-repressor MITR (MEF-2 interacting transcription repressor) also down-regulates MEF-2 activity via recruitment of HDAC1 (37).

Although the signaling pathways involved in HDAC dissociation from MEF-2 have been delineated in muscle and T-cells, the pathways involved in the active recruitment of HDACs to target promoters are currently unknown. To our knowledge, the GnRH promoter is the only natural promoter negatively regulated by MEF-2 transcription factors. Thus, it will be interesting to investigate whether Ark signaling results in MEF-2-dependent recruitment of HDACs or other co-repressor proteins to the GnRH promoter to inhibit transcription. Our preliminary studies to dissect the signaling components required for Ark inhibition of the GnRH promoter suggest that calcium pathways are not involved.2 Therefore, if Ark stimulates HDAC association with MEF-2 proteins bound to the GnRH promoter, signal-dependent recruitment of HDACs is likely to occur through a different mechanism than that of HDAC release. Ultimately, studying the Ark signaling pathways that converge on MEF-2B/2C and the putative homeoprotein will further elucidate the general mechanisms governing negative regulation of gene expression as well as expand our understanding of how the GnRH gene is modulated across development.


    ACKNOWLEDGEMENTS

We thank the many investigators who contributed reagents used in these studies, as well as Rachel Henderson for generating the DIG probes. We are also especially grateful to Kim Heidenreich, John Pawlowski, and Peter Watson for many helpful discussions regarding this work.


    FOOTNOTES

* This work was supported by National Institute of Child Health and Human Development Grants HD31191-03 (to M. E. W.), HD33441 (to G. Schwarting and S. A. T.), and a Lalor Fellowship (to M. P. A.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Veterans Affairs Medical Center, Box 111H, 1055 Clermont St., Denver, CO 80220. Tel: 303-399-8020 (ext. 3137); Fax: 303-393-5271; E-mail: margaret.wierman@uchsc.edu.

Published, JBC Papers in Press, September 19, 2000, DOI 10.1074/jbc.M007097200

2 M. P. Allen, unpublished observations.


    ABBREVIATIONS

The abbreviations used are: GnRH, gonadotropin releasing hormone; Ark, adhesion related kinase; MEF, myocyte enhancer factor; DIG, digoxigenin; EMSA, electrophoretic mobility shift assay; HDAC, histone deacetylases.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES


1. Schwanzel-Fukuda, M., and Pfaff, D. W. (1989) Nature 338, 161-164
2. Wray, S., Grant, P., and Gainer, H. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 8132-8136
3. Hiatt, E. S., Brunetta, P. G., Seiler, G. R., Barney, S. A., Selles, W. D., Wooledge, K. H., and King, J. C. (1992) Endocrinology 130, 1030-1043
4. King, J. C., and Rubin, B. S. (1995) Cell Mol. Neurobiol. 15, 89-106
5. Radovick, S., Wray, S., Lee, E., Nicols, D. K., Nakayama, Y., Weintraub, B. D., Westphal, H., Cutler, G. B., Jr., and Wondisford, F. E. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3402-3406
6. Mellon, P. L., Windle, J. J., Goldsmith, P. C., Padula, C. A., Roberts, J. L., and Weiner, R. I. (1990) Neuron 5, 1-10
7. Belsham, D. D., and Mellon, P. L. (2000) Mol. Endocrinol. 14, 212-228
8. Clark, M. E., and Mellon, P. L. (1995) Mol. Cell. Biol. 15, 6169-6177
9. Wierman, M. E., Xiong, X., Kepa, J. K., Spaulding, A. J., Jacobsen, B. M., Fang, Z., Nilaver, G., and Ojeda, S. R. (1997) Mol. Cell. Biol. 17, 1652-1665
10. Bruder, J. M., Spaulding, A. J., and Wierman, M. E. (1996) Mol. Endocrinol. 10, 35-44
11. Fang, Z., Xiong, X., James, A., Gordon, D. F., and Wierman, M. E. (1998) Endocrinology 139, 3654-3657
12. O'Bryan, J. P., Frye, R. A., Cogswell, P. C., Neubauer, A., Kitch, B., Prokop, C., Espinosa, R., III, Le Beau, M. M., Earp, H. S., and Liu, E. T. (1991) Mol. Cell. Biol. 11, 5016-5031
13. Janssen, J. W., Schulz, A. S., Steenvoorden, A. C., Schmidberger, M., Strehl, S., Ambros, P. F., and Bartram, C. R. (1991) Oncogene 6, 2113-2120
14. Rescigno, J., Mansukhani, A., and Basilico, C. (1991) Oncogene 6, 1909-1913
15. Crosier, K. E., and Crosier, P. S. (1997) Pathology 29, 131-135
16. Lai, C., and Lemke, G. (1991) Neuron 6, 691-704
17. Bellosta, P., Costa, M., Lin, D. A., and Basilico, C. (1995) Mol. Cell. Biol. 15, 614-625
18. Schulz, N. T., Paulhiac, C. I., Lee, L., and Zhou, R. (1995) Brain Res. Mol. Brain Res. 28, 273-280
19. Mark, M. R., Scadden, D. T., Wang, Z., Gu, Q., Goddard, A., and Godowski, P. J. (1994) J. Biol. Chem. 269, 10720-10728
20. Ohashi, K., Mizuno, K., Kuma, K., Miyata, T., and Nakamura, T. (1994) Oncogene 9, 699-705
21. Fujimoto, J., and Yamamoto, T. (1994) Oncogene 9, 693-698
22. Biscardi, J. S., Denhez, F., Buehler, G. F., Chesnutt, D. A., Baragona, S. C., O'Bryan, J. P., Der, C. J., Fiordalisi, J. J., Fults, D. W., and Maness, P. F. (1996) J. Biol. Chem. 271, 29049-29059
23. Varnum, B. C., Young, C., Elliott, G., Garcia, A., Bartley, T. D., Fridell, Y. W., Hunt, R. W., Trail, G., Clogston, C., and Toso, R. J. (1995) Nature 373, 623-626
24. Chen, J., Carey, K., and Godowski, P. J. (1997) Oncogene 14, 2033-2039
25. Nagata, K., Ohashi, K., Nakano, T., Arita, H., Zong, C., Hanafusa, H., and Mizuno, K. (1996) J. Biol. Chem. 271, 30022-30027
26. Stitt, T. N., Conn, G., Gore, M., Lai, C., Bruno, J., Radziejewski, C., Mattsson, K., Fisher, J., Gies, D. R., and Jones, P. F. (1995) Cell 80, 661-670
27. Manfioletti, G., Brancolini, C., Avanzi, G., and Schneider, C. (1993) Mol. Cell. Biol. 13, 4976-4985
28. Bellosta, P., Zhang, Q., Goff, S. P., and Basilico, C. (1997) Oncogene 15, 2387-2397
29. Goruppi, S., Ruaro, E., Varnum, B., and Schneider, C. (1999) Oncogene 18, 4224-4236
30. Goruppi, S., Ruaro, E., Varnum, B., and Schneider, C. (1997) Mol. Cell. Biol. 17, 4442-4453
31. Goruppi, S., Ruaro, E., and Schneider, C. (1996) Oncogene 12, 471-480
32. Loeser, R. F., Varnum, B. C., Carlson, C. S., Goldring, M. B., Liu, E. T., Sadiev, S., Kute, T. E., and Wallin, R. (1997) Arthritis Rheum. 40, 1455-1465
33. Allen, M. P., Zeng, C., Schneider, K., Xiong, X., Meintzer, M. K., Bellosta, P., Basilico, C., Varnum, B., Heidenreich, K. A., and Wierman, M. E. (1999) Mol. Endocrinol. 13, 191-201
34. Melaragno, M. G., Wuthrich, D. A., Poppa, V., Gill, D., Lindner, V., Berk, B. C., and Corson, M. A. (1998) Circ. Res. 83, 697-704
35. Fridell, Y. W., Villa, J., Jr., Attar, E. C., and Liu, E. T. (1998) J. Biol. Chem. 273, 7123-7126
36. McCloskey, P., Fridell, Y. W., Attar, E., Villa, J., Jin, Y., Varnum, B., and Liu, E. T. (1997) J. Biol. Chem. 272, 23285-23291
37. Sparrow, D. P., Miska, E. A., Langley, E., Reynaud-Deonauth, S., Kotecha, S., Towers, N., Spohr, G., Kouzarides, T., and Mohun, T. J. (1999) EMBO J. 18, 5085-5098
38. Allen, M. P., Swartz, C. D., Tobet, S. A., Varnum, B., and Wierman, M. E. (2000) Soc. Neurosci. Abst. 26, 1352
39. Lu, Q., Gore, M., Zhang, Q., Camenisch, T., Boast, S., Casagranda, F., Lai, C., Skinner, M. K., Klein, R., Matsushima, G. K., Earp, H. S., Goff, S. P., and Lemke, G. (1999) Nature 398, 723-728
40. Fridell, Y. W., Jin, Y., Quilliam, L. A., Burchert, A., McCloskey, P., Spizz, G., Varnum, B., Der, C., and Liu, E. T. (1996) Mol. Cell. Biol. 16, 135-145
41. Black, B. L., and Olson, E. N. (1998) Annu. Rev. Cell Dev. Biol. 14, 167-196
42. Naya, F. S., and Olson, E. (1999) Curr. Opin. Cell Biol. 11, 683-688
43. McDermott, J. C., Cardoso, M. C., Yu, Y. T., Andres, V., Leifer, D., Krainc, D., Lipton, S. A., and Nadal-Ginard, B. (1993) Mol. Cell. Biol. 13, 2564-2577
44. Lyons, G. E., Micales, B. K., Schwarz, J., Martin, J. F., and Olson, E. N. (1995) J. Neurosci. 15, 5727-5738
45. Ikeshima, H., Imai, S., Shimoda, K., Hata, J., and Takano, T. (1995) Neurosci. Lett. 200, 117-120
46. Naya, F. J., Wu, C., Richardson, J. A., Overbeek, P., and Olson, E. N. (1999) Development 126, 2045-2052
47. Lin, X., Shah, S., and Bulleit, R. F. (1996) Brain Res. Mol. Brain Res. 42, 307-316
48. Leifer, D., Golden, J., and Kowall, N. W. (1994) Neuroscience 63, 1067-1079
49. Leifer, D., Krainc, D., Yu, Y. T., McDermott, J., Breitbart, R. E., Heng, J., Neve, R. L., Kosofsky, B., Nadal-Ginard, B., and Lipton, S. A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1546-1550
50. Mao, Z., and Wiedmann, M. (1999) J. Biol. Chem. 274, 31102-31107
51. Mao, Z., Bonni, A., Xia, F., Nadal-Vicens, M., and Greenberg, M. E. (1999) Science 286, 785-790
52. Krainc, D., Bai, G., Okamoto, S., Carles, M., Kusiak, J. W., Brent, R. N., and Lipton, S. A. (1998) J. Biol. Chem. 273, 26218-26224
53. Grayson, J., Bassel-Duby, R., and Williams, R. S. (1998) J. Cell. Biochem. 70, 366-375
54. Lakich, M. M., Diagana, T. T., North, D. L., and Whalen, R. G. (1998) J. Biol. Chem. 273, 15217-15226
55. Lee, Y., Nadal-Ginard, B., Mahdavi, V., and Izumo, S. (1997) Mol. Cell. Biol. 17, 2745-2755
56. Morin, S., Charron, F., Robitaille, L., and Nemer, M. (2000) EMBO J. 19, 2046-2055
57. Wu, H., Naya, F. J., McKinsey, T. A., Mercer, B., Shelton, J. M., Chin, E. R., Simard, A. R., Michel, R. N., Bassel-Duby, R., Olson, E. N., and Williams, R. S. (2000) EMBO J. 19, 1963-1973
58. Black, B. L., Ligon, K. L., Zhang, Y., and Olson, E. N. (1996) J. Biol. Chem. 271, 26659-26663
59. Mao, Z., and Nadal-Ginard, B. (1996) J. Biol. Chem. 271, 14371-14375
60. Firulli, A. B., Miano, J. M., Bi, W., Johnson, A. D., Casscells, W., Olson, E. N., and Schwarz, J. J. (1996) Circ. Res. 78, 196-204
61. Maxwell, I. H., Harrison, G. S., Wood, W. M., and Maxwell, F. (1989) BioTechniques 7, 276-280
62. Kepa, J. K., Wang, C., Neeley, C. I., Raynolds, M. V., Gordon, D. F., Wood, W. M., and Wierman, M. E. (1992) Nucleic Acids Res. 20, 1393-1399
63. Kepa, J. K., Spaulding, A. J., Jacobsen, B. M., Fang, Z., Xiong, X., Radovick, S., and Wierman, M. E. (1996) Nucleic Acids Res. 24, 3614-3620
64. Kepa, J. K., Neeley, C. I., Jacobsen, B. M., Bruder, J. M., Meintzer, M. K., McDonnell, D. P., Leslie, K. K., and Wierman, M. E. (1994) Endocrine 2, 947-956
65. Chalepakis, G., Arnemann, J., Slater, E., Bruller, H. J., Gross, B., and Beato, M. (1988) Cell 53, 371-382
66. Astruc, M. E., Chabret, C., Bali, P., Gagne, D., and Pons, M. (1995) Endocrinology 136, 824-832
67. Han, J., Jiang, Y., Li, Z., Kravchenko, V. V., and Ulevitch, R. J. (1997) Nature 386, 296-299
68. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489
69. Osborn, M. T., Herrin, K., Buzen, F. G., Hurlburt, B. K., and Chambers, T. C. (1999) BioTechniques 27, 887-90, 892
70. Tobet, S. A., Hanna, I. K., and Schwarting, G. A. (1996) Brain Res. Dev. Brain Res. 97, 287-292
71. Bless, E. P., Westaway, W. A., Schwarting, G. A., and Tobet, S. A. (2000) Endocrinology 141, 1254-1262
72. Schug, J., and Overton, C. G. (1997) TESS: Transcription Element Search Software on the WWW, Technical Report CBIL-TR-1997-1001-v0 (0) , Computational Biology and Informatics Laboratory, School of Medicine, University of Pennsylvania
73. Li, P., He, X., Gerrero, M. R., Mok, M., Aggarwal, A., and Rosenfeld, M. G. (1993) Genes Dev. 7, 2483-2496
74. Kelley, C. G., Lavorgna, G., Clark, M. E., Boncinelli, E., and Mellon, P. L. (2000) Mol. Endocrinol. 14, 1246-1256
75. Lu, J., McKinsey, T. A., Nicol, R. L., and Olson, E. N. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 4070-4075
76. Youn, H. D., Sun, L., Prywes, R., and Liu, J. O. (1999) Science 286, 790-793


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
EndocrinologyHome page
S. M. Nielsen-Preiss, M. P. Allen, M. Xu, D. A. Linseman, J. E. Pawlowski, R. J. Bouchard, B. C. Varnum, K. A. Heidenreich, and M. E. Wierman
Adhesion-Related Kinase Induction of Migration Requires Phosphatidylinositol-3-Kinase and Ras Stimulation of Rac Activity in Immortalized Gonadotropin-Releasing Hormone Neuronal Cells
Endocrinology, June 1, 2007; 148(6): 2806 - 2814.
[Abstract] [Full Text] [PDF]